Show simple item record

dc.contributor.authorPaulsen, Benedikte
dc.contributor.authorSkille, Hanne
dc.contributor.authorSmith, Erin N.
dc.contributor.authorHveem, Kristian
dc.contributor.authorGabrielsen, Maiken Elvestad
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorRosendaal, Frits Richard
dc.contributor.authorFrazer, Kelly A.
dc.contributor.authorGran, Olga Vikhammer
dc.contributor.authorHansen, John-Bjarne
dc.date.accessioned2020-02-20T08:46:23Z
dc.date.available2020-02-20T08:46:23Z
dc.date.issued2019-10-03
dc.description.abstractVenous thromboembolism is a frequent complication in patients with cancer. Homozygous carriers of the fibrinogen gamma gene (FGG) rs2066865 have a moderately increased risk of venous thromboembolism, but the effect of the FGG variant in cancer is unknown. We aimed to investigate the effect of the FGG variant and active cancer on the risk of venous thromboembolism. Cases with incident venous thromboembolism (n= 640) and a randomly selected age-weighted sub-cohort (n=3734) were derived from a population-based cohort (the Tromso study). Cox-regression was used to estimate hazard ratios with 95% confidence intervals for VTE according to categories of cancer and FGG. In those without cancer, homozygosity at the FGG variant was associated with a 70% (HR 1.7 95% CI 1.2-2.3) increased risk of venous thromboembolism compared to non-carriers. Cancer patients homozygous for the FGG variant had a 2-fold (HR 2.0 95% CI 1.1-3.6) higher risk of venous thromboembolism than cancer patients without the variant. Moreover, the 6-month cumulative incidence of venous thromboembolism among cancer patients was 6.4% (95% CI, 3.5%-11.6%) in homozygous carriers of FGG and 3.1% (95% CI, 2.3%-4.7%) in those without risk alleles. A synergistic effect was observed between rs2066865 and active cancer on the risk of VTE (Synergy index: 1.81, 95% CI: 1.02-3.21, Attributable proportion: 0.43, 95% CI: 0.11-0.74). In conclusion, homozygosity at the FGG variant and active cancer yielded synergistic effect on the risk of venous thromboembolism.en_US
dc.descriptionCreative Commons Attribution Non-Commercial License <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0. </a>en_US
dc.identifier.citationPaulsen B, Skille HS, Smith EN, Hveem K, Gabrielsen ME, Brækkan SK, Rosendaal FR, Frazer KA, Gran O, Hansen JB. Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism. Haematologica. 2019en_US
dc.identifier.cristinIDFRIDAID 1773448
dc.identifier.doi10.3324/haematol.2019.224279
dc.identifier.issn0390-6078
dc.identifier.issn1592-8721
dc.identifier.urihttps://hdl.handle.net/10037/17430
dc.language.isoengen_US
dc.publisherFerrata Storti Foundationen_US
dc.relation.journalHaematologica
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright © 2019, Ferrata Storti Foundationen_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleFibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolismen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record